Menopause, Hormones, and Cardiovascular Vulnerability in Women

Archives of Internal Medicine

Volumn 164, Issue 5, 2004, Pages 479-481

  Kannel, William B ^a   Levy, Daniel ^b  

^a Framingham Heart Study ^*

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; ESTROGEN THERAPY; FIBRINOLYSIS; HEART PROTECTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 1542317532     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.5.479     Document Type: Note

References (23)

1. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288: 321-333.
2. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
3. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
4. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002; 89(suppl):12E-18E.
5. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Saul PW. Estrogen receptor alpha mediates the non-genomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:401-406.
6. Stampfer MJ, Colditz GA, Witlett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
7. Shipak Mg, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a) and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
8. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117: 1016-1037.
9. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen-progestogen in postmenopausal women. Ann Intern Med. 1997;127:501-508.
10. Hernandez Avila M, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1990;1:128-133.
11. Wilson PWF, Garrison RJ, Castelli WP. Postmenopaual estrogen use, cigarette smoking, and cardiovascular disease: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
12. Stampfer M, Colditz G, Estrogen replacement therapy for coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
13. Karas RH, Mosca L. Introduction to a symposium on hormone replacement therapy and the pathophysiology of cardiovascular disease. Am J Cardiol. 2002;90:1F-6F.
14. Mosca L, Collins P, Heerington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for health care professionals from the America Heart Association. Circulation. 2001;104:499-503.
15. Coronary Drug Project Research Group. The Coronary Drug Project findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA. 1973;226:652.
16. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973;32:1126.
17. Drill VA. Oral contraceptives and thromboembolic disease. JAMA. 1972;219:583.
18. Grodstein F, Manson JE, Colditz GA, et al. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133: 933-941.
19. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med. 2001;135:1-8.
20. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447-452.
21. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med. 1978;89: 157-161.
22. Ritterband AB, Jaffe IA, Densen PM, Magagna JF, Reed E. Gonadal function and the development of coronary heart disease. Circulation. 1963;27:237-251.
23. Gebara C, Mittleman M, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.